Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial.

ABSTRACT:

Objective

Anorexia nervosa is complicated by high bone resorption, low bone mineral density (BMD), and increased fracture risk. We investigated whether off-label antiresorptive therapy with denosumab increases BMD in women with anorexia nervosa.

Design

Twelve-month, randomized, double-blind, placebo-controlled study.

Methods

Thirty ambulatory women with anorexia nervosa and areal BMD (aBMD) T-score <-1.0 at ≥1 sites were randomized to 12 months of denosumab (60 mg subcutaneously q6 months)(n = 20) or placebo (n = 10). Primary end point was postero-anterior (PA) lumbar spine aBMD by dual-energy x-ray absorptiometry. Secondary end points included femoral neck aBMD, tibia and radius volumetric BMD and bone microarchitecture by high-resolution peripheral quantitative CT,

SUBMITTER: Haines MS 

PROVIDER: S-EPMC9746654 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature